Effect of Clcitriol in Ischemi stroke

Phase 2

Recruiting

• Conditions: Ischemic Stroke.; Cerebral infarction due to thrombosis of unspecified precerebral artery; I63.00

• Registration Number: IRCT20210101049905N2
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

Age 18 to 85 years
Focal neurological disorder
Clinical diagnosis of acute ischemic stroke
Radiological findings of MRI and CT are consistent with the clinical diagnosis of acute hemisphere stroke
Patients who have been hospitalized for the first 24 hours after a stroke.
Patients suffering from ischemic stroke for the first time

Exclusion Criteria

Evidence based on acute or chronic intracerebral hemorrhage and cerebral aneurysm
Existence of any etiology other than ischemia
Existence of any cognitive or behavioral disorders that lead to the patient not cooperating.
Consumption of any combination or drug with antioxidant effects except prescription drugs
Existence of another concomitant inflammatory disease
Taking medications other than standard ischemic stroke treatments that alter the levels of the factors under consideration.
Pregnancy and lactation
Use any combination with antioxidant and anti-inflammatory effects in the past month
Asthma and a history of anaphylactic shock
Taking drugs that interfere with calcitriol

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interleukin 6. Timepoint: At the beginning of the study and 3 days after the end of the medication. Method of measurement: ELISA test.;National Institutes of Health Stroke Scale score. Timepoint: At the beginning of the study and 90 days after the end of the medication. Method of measurement: NIHSS questionnaire.